JP2014218516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014218516A5 JP2014218516A5 JP2014165392A JP2014165392A JP2014218516A5 JP 2014218516 A5 JP2014218516 A5 JP 2014218516A5 JP 2014165392 A JP2014165392 A JP 2014165392A JP 2014165392 A JP2014165392 A JP 2014165392A JP 2014218516 A5 JP2014218516 A5 JP 2014218516A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- carrier protein
- sialic acid
- meningitidis
- serogroup
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001720 carbohydrates Chemical class 0.000 claims description 15
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 13
- 238000006640 acetylation reaction Methods 0.000 claims description 11
- 229920001519 homopolymer Polymers 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 5
- FZLJPEPAYPUMMR-UOLFYFMNSA-L [(2S,3S,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OP([O-])([O-])=O FZLJPEPAYPUMMR-UOLFYFMNSA-L 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 17
- 102000014914 Carrier Proteins Human genes 0.000 claims 15
- 108010078791 Carrier Proteins Proteins 0.000 claims 15
- 102000038129 antigens Human genes 0.000 claims 9
- 108091007172 antigens Proteins 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 8
- 208000001877 Whooping Cough Diseases 0.000 claims 3
- 239000000969 carrier Substances 0.000 claims 3
- 201000005702 pertussis Diseases 0.000 claims 3
- 108060007869 BAH1 Proteins 0.000 claims 2
- 102100019937 DHRS2 Human genes 0.000 claims 2
- 241000588650 Neisseria meningitidis Species 0.000 claims 2
- 229940052778 Neisseria meningitidis Drugs 0.000 claims 2
- 229960003983 diphtheria toxoid Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 1
- 206010013023 Diphtheria Diseases 0.000 claims 1
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 1
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 229940047650 Haemophilus influenzae Drugs 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 241000709721 Hepatovirus A Species 0.000 claims 1
- 208000006572 Human Influenza Diseases 0.000 claims 1
- 206010022000 Influenza Diseases 0.000 claims 1
- 241000588677 Neisseria meningitidis serogroup B Species 0.000 claims 1
- 229940031000 Streptococcus pneumoniae Drugs 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 206010043376 Tetanus Diseases 0.000 claims 1
- 230000036462 Unbound Effects 0.000 claims 1
- 230000001413 cellular Effects 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims 1
- 229910052753 mercury Inorganic materials 0.000 claims 1
- 229960000814 tetanus toxoid Drugs 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 2
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 1
- 210000001009 Nucleus accumbens Anatomy 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
Description
これら4種の血清群の各々の莢膜糖は、良く特徴付けられている。血清群A髄膜炎菌の莢膜糖は、C3位とC4位とに部分的なO−アセチル化を有する、(α1→6)連結型N−アセチル−D−マンノサミン−1−リン酸のホモポリマーである。このアセチル基は、加水分解を防止するブロック基(blocking group)により置換され得[30]、そして、このような修飾糖は、依然として本発明の意味の範囲内の血清群A糖である。血清群Cの莢膜糖は、(α2→9)連結型シアル酸(N−アセチルノイラミン酸または「NeuNAc」)のホモポリマーである。大半の血清群C株は、シアル酸残基のC−7および/またはC−8においてO−アセチル基を有するが、臨床単離物のうちの約15%は、これらのO−アセチル基を欠いている[31、32]。糖の構造は、→9)−Neu p NAc 7/8 OAc−(α2→のように記載される。血清群W135糖は、シアル酸−ガラクトース二糖単位のポリマーである。血清群C糖と同様に、これは種々のO−アセチル化を有するが、それはシアル酸の7位と9位におけるものである[33]。この構造は、→4)−D−Neup5Ac(7/9OAc)−α−(2→6)−D−Gal−α−(1→のように記載される。血清群Y糖は、二糖の反復単位がガラクトースの代わりにグルコースを含むことを除いて、血清群W135糖に類似する。血清群W135と同様に、これは、シアル酸の7位と9位における種々のO−アセチル化を有する[33]。血清群Yの構造は、→4)−D−Neup5Ac(7/9OAc)−α−(2→6)−D−Glc−α−(1→のように記載される。
Claims (12)
- Neisseria meningitidisによって引き起こされる疾患に対して患者を免疫するための組成物であって、該組成物は、(a)(i)C3位とC4位とに部分的なO−アセチル化を有する、(α1→6)連結型N−アセチル−D−マンノサミン−1−リン酸のホモポリマーである血清群AのN.meningitidisの莢膜糖と(ii)キャリアタンパク質との結合体;(b)(i)シアル酸の7位と8位とに可変のO−アセチル化を有する、(α2→9)連結型シアル酸のホモポリマーである血清群CのN.meningitidisの莢膜糖と(ii)キャリアタンパク質との結合体;(c)(i)シアル酸の7位と9位とに可変のO−アセチル化を有する、シアル酸−ガラクトース二糖単位のポリマーである血清群W135のN.meningitidisの莢膜糖と(ii)キャリアタンパク質との結合体;および(d)(i)シアル酸の7位と9位とに可変のO−アセチル化を有する、シアル酸−グルコース二糖単位のポリマーである血清群YのN.meningitidisの莢膜糖と(ii)キャリアタンパク質との結合体、を含有し、
ここで、該結合体(a)、(b)、(c)および(d)は、同じキャリアタンパク質(「共通キャリア」)を使用し、そして、該組成物は、該共通キャリアを非結合体化形態で、0.01μg/mlより高く、2.0μg/mlより低い濃度で含む、組成物。 - 前記髄膜炎菌結合体の各々が、ジフテリアトキソイド;破傷風トキソイド;CRM197;およびH.influenzae由来のプロテインDから選択されるキャリアタンパク質に結合体化されている、請求項1に記載の組成物。
- 前記キャリアタンパク質が、ジフテリアトキソイドである、請求項2に記載の組成物。
- 前記キャリアタンパク質が、H.influenzaeのプロテインDである、請求項2に記載の組成物。
- 筋肉内注射のために処方されている、請求項1に記載の組成物。
- 前記組成物が、水銀物質を全く含まない、請求項1に記載の組成物。
- 水性形態である、請求項1に記載の組成物。
- 凍結乾燥形態である、請求項1に記載の組成物。
- 前記組成物中のキャリアタンパク質の全体での濃度が、100μg/ml未満である、請求項1に記載の組成物。
- 請求項1に記載の組成物であって、(i)B型Haemophilus influenzae由来の結合体化された莢膜糖;(ii)Streptococcus pneumoniae由来の結合体化された莢膜糖;(iii)N.meningitidis 血清群B由来のタンパク質抗原;(iv)ジフテリア抗原;(v)破傷風抗原;(vi)細胞性百日咳抗原もしくは全細胞百日咳抗原;(vii)1種以上の無細胞百日咳抗原;(viii)B型肝炎ウイルス由来の抗原;(ix)1種以上のポリオウイルス抗原;(x)A型肝炎ウイルス由来の抗原のうちの1つ以上のさらなる抗原をさらに含有する、組成物。
- Neisseria meningitidisによって引き起こされる疾患に対して患者を免疫するための組成物を調製するためのプロセスであって、該プロセスは、以下の工程:
(1)(a)(i)C3位とC4位とに部分的なO−アセチル化を有する、(α1→6)連結型N−アセチル−D−マンノサミン−1−リン酸のホモポリマーである血清群AのN.meningitidisの莢膜糖と(ii)キャリアタンパク質との結合体;(b)(i)シアル酸の7位と8位とに可変のO−アセチル化を有する、(α2→9)連結型シアル酸のホモポリマーである血清群CのN.meningitidisの莢膜糖と(ii)キャリアタンパク質との結合体;(c)(i)シアル酸の7位と9位とに可変のO−アセチル化を有する、シアル酸−ガラクトース二糖単位のポリマーである血清群W135のN.meningitidisの莢膜糖と(ii)キャリアタンパク質との結合体;(d)(i)シアル酸の7位と9位とに可変のO−アセチル化を有する、シアル酸−グルコース二糖単位のポリマーである血清群YのN.meningitidisの莢膜糖と(ii)キャリアタンパク質との結合体、を調製する工程であって、
ここで、該結合体(a)、(b)、(c)および(d)は、同じキャリアタンパク質(「共通キャリア」)を使用する、工程;ならびに
(2)結合体を混合して、該共通キャリアを非結合体化形態で、0.01μg/mlより高く、2.0μg/mlより低い濃度で含有する組成物を得る工程
を包含する、プロセス。 - 非結合体化キャリアタンパク質の量を測定する1以上の工程をさらに包含する、請求項11に記載のプロセス。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0409745.7 | 2004-04-30 | ||
GBGB0409745.7A GB0409745D0 (en) | 2004-04-30 | 2004-04-30 | Compositions including unconjugated carrier proteins |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012171122A Division JP2012214498A (ja) | 2004-04-30 | 2012-08-01 | 共通キャリアタンパク質を有する混合型髄膜炎菌結合体 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016001516A Division JP2016053088A (ja) | 2004-04-30 | 2016-01-07 | 共通キャリアタンパク質を有する混合型髄膜炎菌結合体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014218516A JP2014218516A (ja) | 2014-11-20 |
JP2014218516A5 true JP2014218516A5 (ja) | 2016-11-04 |
JP6035293B2 JP6035293B2 (ja) | 2016-11-30 |
Family
ID=32482499
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007510159A Withdrawn JP2007535531A (ja) | 2004-04-30 | 2005-04-29 | 共通キャリアタンパク質を有する混合型髄膜炎菌結合体 |
JP2012171122A Pending JP2012214498A (ja) | 2004-04-30 | 2012-08-01 | 共通キャリアタンパク質を有する混合型髄膜炎菌結合体 |
JP2014165392A Active JP6035293B2 (ja) | 2004-04-30 | 2014-08-15 | 共通キャリアタンパク質を有する混合型髄膜炎菌結合体 |
JP2016001516A Pending JP2016053088A (ja) | 2004-04-30 | 2016-01-07 | 共通キャリアタンパク質を有する混合型髄膜炎菌結合体 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007510159A Withdrawn JP2007535531A (ja) | 2004-04-30 | 2005-04-29 | 共通キャリアタンパク質を有する混合型髄膜炎菌結合体 |
JP2012171122A Pending JP2012214498A (ja) | 2004-04-30 | 2012-08-01 | 共通キャリアタンパク質を有する混合型髄膜炎菌結合体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016001516A Pending JP2016053088A (ja) | 2004-04-30 | 2016-01-07 | 共通キャリアタンパク質を有する混合型髄膜炎菌結合体 |
Country Status (23)
Country | Link |
---|---|
US (1) | US9492558B2 (ja) |
EP (2) | EP2108374A1 (ja) |
JP (4) | JP2007535531A (ja) |
CN (1) | CN1976716B (ja) |
AT (1) | ATE439144T1 (ja) |
AU (1) | AU2005237308B2 (ja) |
BR (1) | BRPI0510440A (ja) |
CA (1) | CA2564366C (ja) |
CY (1) | CY1109582T1 (ja) |
DE (1) | DE602005015961D1 (ja) |
DK (1) | DK1755662T3 (ja) |
ES (1) | ES2329059T3 (ja) |
GB (1) | GB0409745D0 (ja) |
HK (1) | HK1100428A1 (ja) |
HR (1) | HRP20090607T8 (ja) |
MX (1) | MXPA06012330A (ja) |
NZ (1) | NZ550601A (ja) |
PL (1) | PL1755662T3 (ja) |
PT (1) | PT1755662E (ja) |
RS (1) | RS51192B (ja) |
RU (1) | RU2385737C2 (ja) |
SI (1) | SI1755662T1 (ja) |
WO (1) | WO2005105141A2 (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4812942B2 (ja) * | 1999-02-26 | 2011-11-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | CGモチーフを含むオリゴヌクレオチドを用いるNeisseria抗原殺菌活性の増強 |
GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
GB0505518D0 (en) | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
MX2007016402A (es) * | 2005-06-27 | 2008-03-07 | Glaxosmithkline Biolog Sa | Composicion inmunogenica. |
JP2009520771A (ja) * | 2005-12-23 | 2009-05-28 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | コンジュゲートワクチン |
US10828361B2 (en) | 2006-03-22 | 2020-11-10 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
SI2004225T1 (sl) | 2006-03-22 | 2012-08-31 | Novartis Ag | Reĺ˝imi za imunizacijo z meningokoknimi konjugati |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
US20100203137A1 (en) * | 2007-06-04 | 2010-08-12 | Mario Contorni | Formulation of meningitis vaccines |
EP2200642B1 (en) * | 2007-10-19 | 2012-04-18 | Novartis AG | Meningococcal vaccine formulations |
AU2013204315B2 (en) * | 2007-10-19 | 2016-02-18 | Glaxosmithkline Biologicals Sa | Meningococcal vaccine formulations |
GB0822633D0 (en) * | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
BR112013004236A2 (pt) | 2010-08-23 | 2016-07-12 | Wyeth Llc | formulações estáveis de antígenos de neisseria meningitidis rlp2086 |
ES2728282T3 (es) | 2010-09-10 | 2019-10-23 | Wyeth Llc | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis |
KR101784644B1 (ko) | 2012-03-09 | 2017-10-11 | 화이자 인코포레이티드 | 수막염균 조성물 및 이의 사용 방법 |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
KR102057217B1 (ko) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
KR20140075196A (ko) * | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
WO2014138290A1 (en) * | 2013-03-05 | 2014-09-12 | Trudeau Institute, Inc. | Compositions and methods for treating bacterial infections |
US9802987B2 (en) | 2013-03-08 | 2017-10-31 | Pfizer Inc. | Immunogenic fusion polypeptides |
CN105188743A (zh) * | 2013-03-18 | 2015-12-23 | 葛兰素史密丝克莱恩生物有限公司 | 治疗方法 |
KR20180099912A (ko) | 2013-09-08 | 2018-09-05 | 화이자 인코포레이티드 | 나이세리아 메닌지티디스 조성물 및 그의 방법 |
KR20190049940A (ko) | 2015-02-19 | 2019-05-09 | 화이자 인코포레이티드 | 나이세리아 메닌지티디스 조성물 및 그의 방법 |
JP6764021B2 (ja) | 2016-09-02 | 2020-09-30 | サノフィ パスツール インコーポレイテッド | ナイセリア・メニンギティディスのワクチン |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
KR20220011796A (ko) | 2017-01-31 | 2022-01-28 | 화이자 인코포레이티드 | 네이세리아 메닌기티디스 조성물 및 그의 방법 |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB323103A (en) | 1928-12-07 | 1929-12-24 | Fred Cunningham Firth | Improvements relating to shaper mechanism for winding yarn on weft bobbins in spinning mules |
US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
US4663160A (en) | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
US4761283A (en) | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
US4882317A (en) | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NL8802046A (nl) | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
AU627226B2 (en) | 1988-08-25 | 1992-08-20 | Liposome Company, Inc., The | Influenza vaccine and novel adjuvants |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
US7118757B1 (en) * | 1988-12-19 | 2006-10-10 | Wyeth Holdings Corporation | Meningococcal class 1 outer-membrane protein vaccine |
ES2055785T3 (es) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas. |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
WO1991001146A1 (en) | 1989-07-14 | 1991-02-07 | Praxis Biologics, Inc. | Cytokine and hormone carriers for conjugate vaccines |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
ATE128628T1 (de) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff. |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
DE122010000016I1 (de) | 1992-05-23 | 2010-07-08 | Glaxosmithkline Biolog Sa | Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten |
ES2142346T3 (es) | 1992-06-18 | 2000-04-16 | Harvard College | Adn, polipeptido, celula, composicion y vacunas contra la toxina de la difteria. |
DK0761231T3 (da) | 1992-06-25 | 2000-05-08 | Smithkline Beecham Biolog | Vaccinepræparat indeholdende adjuvanser |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
DK0658118T3 (da) | 1992-08-31 | 2002-05-06 | Baxter Healthcare Sa | Vaccine mod Neisseria meningitidis, gruppe C |
US5425946A (en) | 1992-08-31 | 1995-06-20 | North American Vaccine, Inc. | Vaccines against group C Neisseria meningitidis |
KR100310510B1 (ko) | 1993-03-23 | 2002-07-04 | 장 스테판느 | 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 |
DE122009000058I1 (de) | 1993-09-22 | 2009-12-31 | Jackson H M Found Military Med | Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
FR2734484B1 (fr) | 1995-05-24 | 1997-06-27 | Pasteur Merieux Serums Vacc | Composition vaccinale liquide et procede de fabrication |
NZ311000A (en) | 1995-06-07 | 1999-04-29 | Smithkline Beecham Biolog | Vaccine comprising a polysaccharide antigen-carrier protein conjugate and a free carrier protein |
DE69612198T3 (de) | 1995-06-23 | 2011-08-18 | Smithkline Beecham Biologicals S.A. | Eine Impfstoffzusammensetzung, bestehend aus einem Haemophilus influenzae B Polysaccharid Antigen-Konjugat adsorbiert an Aluminiumphosphat |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
US6248334B1 (en) * | 1997-01-08 | 2001-06-19 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process |
JP5087758B2 (ja) | 1997-03-10 | 2012-12-05 | オタワ ホスピタル リサーチ インスティチュート | アジュバントとして非メチル化CpGジヌクレオチドを含む核酸の使用 |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
FR2763244B1 (fr) | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
ES2298316T3 (es) | 1997-09-05 | 2008-05-16 | Glaxosmithkline Biologicals S.A. | Emulsiones de aceite en agua que contienen saponinas. |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
EP1053021B1 (en) * | 1998-02-05 | 2009-01-21 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media |
KR100585408B1 (ko) | 1998-02-12 | 2006-06-01 | 와이어쓰 홀딩스 코포레이션 | 인터루킨-12로 제형된 폐렴구균 및 수막구균 백신 |
US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
CN1296416A (zh) | 1998-04-09 | 2001-05-23 | 史密丝克莱恩比彻姆生物有限公司 | 佐剂组合物 |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
EP1109576B1 (en) | 1998-08-19 | 2009-10-21 | Baxter Healthcare SA | Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide |
PL201482B1 (pl) | 1998-10-16 | 2009-04-30 | Smithkline Beecham Biolog | Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki |
US6585973B1 (en) * | 1998-10-29 | 2003-07-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method for preparing solid phase conjugated vaccine |
EP1162999B1 (en) | 1999-03-19 | 2006-11-29 | Glaxosmithkline Biologicals S.A. | Vaccine against Streptococcus pneumoniae |
WO2000061761A2 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
PL355163A1 (en) | 1999-09-24 | 2004-04-05 | Smithkline Beecham Biologicals S.A. | Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
AU766635B2 (en) | 1999-09-24 | 2003-10-23 | Smithkline Beecham Biologicals (Sa) | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
EP2292263A3 (en) | 1999-12-02 | 2011-07-27 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for stabilizing biological molecules upon lyophilization |
WO2001095935A1 (en) | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
ATE534402T1 (de) * | 2000-06-29 | 2011-12-15 | Smithkline Beecham Biolog | Multivalente impfstoffzusammensetzung |
GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
DE60132471T2 (de) | 2000-09-26 | 2009-01-15 | Idera Pharmaceuticals, Inc., Cambridge | Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen |
YU66103A (sh) * | 2001-01-23 | 2006-05-25 | Aventis Pasteur | Vakcina multivalentnog konjugata meningokokalnog polisaharid-proteina |
US20030035806A1 (en) | 2001-05-11 | 2003-02-20 | D'ambra Anello J. | Novel meningitis conjugate vaccine |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
CA2452720C (en) | 2001-07-26 | 2012-04-17 | Chiron S.R.L. | Vaccines comprising aluminium adjuvants and histidine |
US20030091593A1 (en) | 2001-09-14 | 2003-05-15 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
DK1450856T3 (da) | 2001-09-14 | 2010-05-31 | Cytos Biotechnology Ag | Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
DK1490409T3 (da) | 2002-03-26 | 2009-03-23 | Novartis Vaccines & Diagnostic | Modificerede saccharider med forbedret stabilitet i vand |
CN1809380B (zh) | 2002-10-11 | 2010-05-12 | 启龙有限公司 | 广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗 |
CN102319427A (zh) | 2003-01-30 | 2012-01-18 | 诺华疫苗和诊断有限公司 | 抗多种脑膜炎球菌血清组的可注射性疫苗 |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
-
2004
- 2004-04-30 GB GBGB0409745.7A patent/GB0409745D0/en not_active Ceased
-
2005
- 2005-04-29 PT PT05740675T patent/PT1755662E/pt unknown
- 2005-04-29 EP EP09075339A patent/EP2108374A1/en not_active Ceased
- 2005-04-29 AT AT05740675T patent/ATE439144T1/de active
- 2005-04-29 RS RSP-2009/0478A patent/RS51192B/sr unknown
- 2005-04-29 US US11/587,101 patent/US9492558B2/en active Active
- 2005-04-29 CA CA2564366A patent/CA2564366C/en active Active
- 2005-04-29 CN CN200580013875.4A patent/CN1976716B/zh active Active
- 2005-04-29 DK DK05740675T patent/DK1755662T3/da active
- 2005-04-29 JP JP2007510159A patent/JP2007535531A/ja not_active Withdrawn
- 2005-04-29 DE DE602005015961T patent/DE602005015961D1/de active Active
- 2005-04-29 RU RU2006142156/13A patent/RU2385737C2/ru active
- 2005-04-29 ES ES05740675T patent/ES2329059T3/es active Active
- 2005-04-29 PL PL05740675T patent/PL1755662T3/pl unknown
- 2005-04-29 NZ NZ550601A patent/NZ550601A/en unknown
- 2005-04-29 SI SI200530814T patent/SI1755662T1/sl unknown
- 2005-04-29 EP EP05740675A patent/EP1755662B1/en not_active Revoked
- 2005-04-29 AU AU2005237308A patent/AU2005237308B2/en active Active
- 2005-04-29 BR BRPI0510440-8A patent/BRPI0510440A/pt not_active Application Discontinuation
- 2005-04-29 MX MXPA06012330A patent/MXPA06012330A/es active IP Right Grant
- 2005-04-29 WO PCT/IB2005/001536 patent/WO2005105141A2/en active Application Filing
-
2007
- 2007-08-06 HK HK07108564.2A patent/HK1100428A1/xx not_active IP Right Cessation
-
2009
- 2009-11-06 CY CY20091101156T patent/CY1109582T1/el unknown
- 2009-11-11 HR HR20090607T patent/HRP20090607T8/xx unknown
-
2012
- 2012-08-01 JP JP2012171122A patent/JP2012214498A/ja active Pending
-
2014
- 2014-08-15 JP JP2014165392A patent/JP6035293B2/ja active Active
-
2016
- 2016-01-07 JP JP2016001516A patent/JP2016053088A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014218516A5 (ja) | ||
TWI720448B (zh) | 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途 | |
JP5718960B2 (ja) | 免疫原性組成物 | |
TWI748810B (zh) | 包含結合之莢膜醣抗原的免疫原組合物及其用途 | |
RU2006142156A (ru) | Объединенные менингококковые конъюгаты с общим белком-носителем | |
JP7120767B2 (ja) | 肺炎球菌ワクチンにおいて用いるための免疫原性組成物 | |
RU2006114695A (ru) | Гипо-и гиперацетилированные менингококковые капсульные сахариды | |
JP2007507578A5 (ja) | ||
JP2008526939A5 (ja) | ||
RU2009149359A (ru) | Состав вакцин против менингита | |
HRP20110685T1 (hr) | Cjepivo od konjugata pneumokoknog polisaharida | |
ATE552844T1 (de) | Injizierbarer impfstoff gegen multiple meningokokken-serogruppen | |
JP2008543908A5 (ja) | ||
JP2008543907A5 (ja) | ||
JP2009525260A5 (ja) | ||
JP2013136639A5 (ja) | ||
MX354103B (es) | Composicion inmunogenica. | |
AU2012203419B2 (en) | Immunogenic composition | |
Chia-Hung et al. | Synthesis of Nesseria meningitidis W135 capsular oligosaccharide with various lengths for immunogenicity comparison |